dostarlimab
gsk
['rectal', 'dostarlimab']
patients (n=12) with mismatch repair deficient, locally advanced rectal cancer had 100% complete response rate to pd1 ab dostarlimab and so far avoided chemoradiation and surgery #asco22 
Medical Oncologist, Cancer Researcher, Drug Developer, ex-@MDAndersonNews, Chief Medical Officer @MonteRosaTx. Views are mine.